Education
About Us
Working with TipRanks
Follow Us
Lipocine Inc (LPCN)
:LPCN
LPCN Stock Chart & Stats
$2.92
-$0.05(-1.04%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.04%)
Day’s Range― - ―
52-Week Range$2.52 - $5.53
Previous CloseN/A
Volume16.76K
Average Volume (3M)48.70K
Market Cap
$14.10M
Enterprise Value$296.40K
Total Cash (Recent Filing)$15.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 05, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding5,551,931
10 Day Avg. Volume28,686
30 Day Avg. Volume48,702
Financial Highlights & Ratios
PEG Ratio-31.18
Price to Book (P/B)1.24
Price to Sales (P/S)2.33
P/FCF Ratio-19.87
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.14
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$7.38Price Target Upside152.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market DemandPerinatal depression is under-diagnosed and under-treated, which may lead to adverse outcomes for the mother and the child, indicating a significant market need for effective treatments like LPCN 1154.
Product AdvantageLPCN 1154 further improves the efficacy and safety profile compared to zuranolone with rapid onset of action and high remission rate.
Regulatory ProgressPhase 3 PPD trial underway with topline results expected, which could support a NDA submission for LPCN 1154 in PPD.
Bears Say
Financial PerformanceNet loss was $2.2M, or ($0.41) per share, in line with the estimated loss.
Regulatory RisksRisks include, but are not limited to: failure of LPCN 1154 in clinical trials and failure to obtain regulatory approval.
Lipocine News
LPCN FAQ
What was Lipocine Inc’s price range in the past 12 months?
Lipocine Inc lowest stock price was $2.52 and its highest was $5.53 in the past 12 months.
What is Lipocine Inc’s market cap?
Lipocine Inc’s market cap is $14.10M.
When is Lipocine Inc’s upcoming earnings report date?
Lipocine Inc’s upcoming earnings report date is Mar 05, 2026 which is in 115 days.
How were Lipocine Inc’s earnings last quarter?
Lipocine Inc released its earnings results on Nov 06, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.05.
Is Lipocine Inc overvalued?
According to Wall Street analysts Lipocine Inc’s price is currently Undervalued.
Does Lipocine Inc pay dividends?
Lipocine Inc does not currently pay dividends.
What is Lipocine Inc’s EPS estimate?
Lipocine Inc’s EPS estimate is -0.59.
How many shares outstanding does Lipocine Inc have?
Lipocine Inc has 5,551,931 shares outstanding.
What happened to Lipocine Inc’s price movement after its last earnings report?
Lipocine Inc reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Lipocine Inc?
Currently, no hedge funds are holding shares in LPCN
Company Description
Lipocine Inc
Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics based on its proprietary drug delivery technology. The company primarily operates in the healthcare sector, specializing in the treatment of metabolic and endocrine disorders, including testosterone deficiency and liver disease. Lipocine's core products include LPCN 1144, an oral testosterone replacement therapy, and LPCN 1107, a treatment for nonalcoholic steatohepatitis (NASH), which leverage its unique lipid-based delivery system to enhance bioavailability and patient compliance.
LPCN Stock 12 Month Forecast
Average Price Target
$7.38
▲(152.74% Upside)
Technical Analysis
Ownership Overview
15.69%
Insiders
5.24% Mutual Funds
<0.01% Other Institutional Investors
75.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---